Completed Projects

HOME > R&D Pipeline > Current status > Completed Projects

KDDF-201212-05 Discovery of vaccine candidate against Staphylococcus aureus infection(Infectious Diseases, Protein) [03.05.2013]

PRINT

Development and Market Objectives

1. To develop and optimize candidate substances for prophylactic vaccines, for the treatment of antibiotic-resistant MRSA infections using virus-derived extracellular vesicles.
2. To provide groundwork for the development of prophylactic vaccines for antibiotic resistant gram-positive bacterial infections based on this technology.
 
 

Unmet Medical Need & Target Patients

1. Target Patients
Those who are susceptible to gram-positive bacterial infection (children and adults over 40)
Patient group for clinical testing: Adult patients expected to need surgery involving skin incision
 
2. Unmet Medical Needs
An estimated 10 to 20 percent of the population carries Staphylococcus aureus, while the infection rate for a fixed period is between 30 and 50 percent. The lifetime infection rate for Staphylococcus aureus is 85 percent. The development of new therapies for this infection is critical as it causes dermatitis, pneumonia, blood poisoning and nosocomial infections arising from antibiotic resistant strains. At present, the development of new antibiotics and vaccines is underway to prevent and cure MRSA, however, new resistant strains are expected to emerge in parallel with the development of new antibiotics. Vaccine development based on existing concepts has been hindered by failure in clinical testing. Therefore, a strong need exists for the development of effective vaccines based on an innovative new paradigm.
 

Status

1. Establishment of a separation technique for extracellular vesicles derived from Staphylococcus aureus.
2. Verification of candidate vaccine effects using extracellular vesicles derived from Staphylococcus aureus. Preventive effects have also been verified for various diseases resulting from infection, involving the effective induction of both antibody (B cell reaction) and T-cell immune reactions.
3. Selection of optimal strain and optimization of candidate vaccine material using bacteria isolated from patients.
 

Intellectual Property

Patents describing extracellular vesicles derived from gram-positive bacteria and their usage have been submitted and are currently under review.
(International application number PCT/KR2010/005721, Priority local application number 10-2009-0083621, Priority PCT international application number PCT/KR2010/001787). Filed locally, as well as in the US, Japan, China and Europe.
 
 

Competitive Advantages

The proposed technology is original and was developed by our principal scientist. Therefore, our institute holds all patent rights for this technology. The details and sources for this technology are as follows:

 

    First-in-class vaccine: Vaccine technology using vesicles secreted from S. aureus is based on the findings of world-first research conducted by our principal scientist. This product is the first candidate vaccine to be based on our original technology.

    Wide spectrum antigenicity: In addition to the specific antigen within the vesicles, another antigen exists in the Staphylococcus genus. Therefore, regardless of the strain, broad specificity may be possible.

    Immunogenicity: To prevent infection, the induction of a Th1 and Th17 immune reaction against S. aureus antigens is crucial, in addition to producing S. aureus antibodies. Within the S. aureus EV, a factor known as PAMP can induce this reaction, effectively leading to an appropriate immune reaction.

    Safety: Vaccines involving extracellular vesicles derived from gram-negative bacteria have the potential to produce partial or systemic side effects. However, no reported partial or systemic side effects have yet been reported for vesicles derived from gram-positive bacteria.

    Epicutaneous application: Vesicles are complex structures that naturally contain antigens and immuno-potentiators. When administered via intramuscular injection or through the skin, desirable immune responses can be readily observed. Application through the skin epidermis is an original technology, which could allow for future vaccines to be more easily administered to children and infants.

    Ease of manufacture: During cultivation of S. aureus, a large numbers of extracellular vesicles are secreted. This circumvents the need for further processing, with simple incubation and refining techniques sufficient for mass production.

Indication

vaccine against Staphylococcus aureus infection

Research Period

Feb. 15th, 2013 to Aug. 14th, 2014

Company

Aeon medix

Developmental Stage

Candidate Selection    

Additional Information

Contact Information

Contact
Address Company Name: AEONmedix
WebSite Homepage: http://www.aeonmedix.com Contact Person: Jeon Seong-gyu
E-mail: gene49@hanmail.net Contact: +82-54-279-8456

Related Projects

Related Project
list
Update to 2013 © KOREA DRUG DEVELOPMENT FUND. ALL RIGHTS RESERVED. QR Code